Navigation Links
Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008

SOUTH SAN FRANCISCO, Calif., Aug. 7 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) announced today that William D. Young, CEO and Chairman, is scheduled to present an update on the company's business at the Thomas Weisel Partners Healthcare Conference on Wednesday, September 3, 2008 at 11:30 a.m. (Eastern Time) at the Four Seasons Hotel in Boston, MA.

To access the live audio broadcast or the subsequent archived recording, log on to and go to the investor relations section ("Investors/Media" tab) and click on the "Events & Webcasts" link provided on the sidebar menu on the page.

About Monogram Biosciences, Inc.

Monogram is advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at


Alfred G. Merriweather

Chief Financial Officer

Tel: 650 624-4576

Jeremiah Hall

Feinstein Kean Healthcare

Tel: 415 677-2700

SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors
2. Monogram Biosciences Announces Second Quarter 2008 Financial Results Conference Call
3. Monogram Biosciences to Present at the Collins Stewart Fourth Annual Growth Conference
4. Sensitivity Enhancements to Monograms Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy
5. Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting
6. Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting
7. Monogram Biosciences Announces First Quarter 2008 Financial Results Conference Call
8. Monogram Biosciences to Present at the JMP Securities Seventh Annual Research Conference
9. Raven biotechnologies Announces Collaboration With Monogram Biosciences to Advance Diagnostic Cancer Technologies
10. Monogram HIV Antibody Assay Is Key Component of Innovative Vaccine Development Program
11. Monogram Announces Promotion of Gordon Parry, PhD, to Vice President, Research and Development, Oncology
Post Your Comments:
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of ... the Cary 5000 and the 6000i models are higher end machines that use the ... of the spectrophotometer’s light beam from the bottom of the cuvette holder. , ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
Breaking Biology Technology:
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
Breaking Biology News(10 mins):